We pioneer end-to-end mammalian protein CDMO solutions to overcome complex biotherapeutic challenges. We empower clients from preclinical R&D to commercial manufacturing, ensuring precision at every step. Explore our integrated services designed for scalability and compliance. Learn more about our CDMO Solutions or dive into mammalian protein CDMO expertise.
Overview of Mammalian Protein CDMO Solutions
As a fully integrated CDMO, we provide end-to-end mammalian protein CDMO solutions designed to accelerate your biologics from concept to clinic and commercial launch. Our platform unites three core service pillars—mammalian protein process development, mammalian protein cGMP manufacturing, and mammalian protein analytical services—into a seamless, high-performance workflow. Leveraging advanced cell line engineering, scalable upstream and downstream platforms, state-of-the-art analytical characterization, and globally compliant cGMP operations, we deliver high-quality protein therapeutics with exceptional consistency and speed. Whether you are advancing early-stage candidates or preparing for commercial supply, our scientific depth, regulatory expertise, and manufacturing excellence ensure a reliable, efficient path from molecule to market.
Our Services
Our integrated service platform delivers scientifically rigorous, phase-appropriate solutions across the entire mammalian protein bioproduction continuum. We navigate complexity to transform your candidate into a consistently manufacturable agent.
Mammalian Protein Process Development
We architect robust, scalable production processes through systematic optimization of cell line development, upstream cultivation, and downstream purification. Our approach begins with high-throughput screening of expression constructs and clonal selection for productivity and critical quality attributes (CQAs). Advanced cell culture development employs metabolic profiling and media/feed optimization to enhance titers while precisely controlling post-translational modifications. Downstream process design utilizes platform purification strategies augmented with molecule-specific refinement, emphasizing viral clearance validation and impurity removal. We implement quality by design (QbD) principles throughout, establishing proven acceptable ranges (PARs) and design spaces for seamless regulatory alignment. Process characterization studies de-risk manufacturing and provide comprehensive control strategy documentation.
Mammalian Protein cGMP Manufacturing
Our flexible manufacturing infrastructure enables seamless transition from clinical to commercial supply. Facilities feature modular single-use bioreactor systems accommodating diverse scales, alongside segregated suites for enhanced containment. Upstream operations leverage advanced perfusion and intensified fed-batch technologies to achieve high cell densities and prolonged viability. Downstream processing incorporates multi-step chromatography purification, viral inactivation/removal, and sophisticated ultrafiltration/diafiltration. Rigorous environmental monitoring, closed processing, and automated systems ensure product integrity. We offer drug substance manufacturing, aseptic fill-finish (liquid and lyophilized presentations), and secondary packaging.
Mammalian Protein Analytical Services
Leveraging state-of-the-art instrumentation and deep scientific expertise, we offer a complete spectrum of analytical services tailored to mammalian protein therapeutics across all development phases.Services include:
- Purity and impurity testing
- Structural characterization
- Functional analysis
- Physicochemical property analysis
- Stability and comparability studies
- Phase-appropriate method development & validation
Our products and services are for research use only.
